Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.

Left atrial appendage occlusion vs continuation of oral anticoagulation therapy alone is linked to reduced ischemic stroke risk in select patients with nonvalvular AF.

WICHITA FALLS (KFDX/KJTL) — While United Regional’s Structural Heart Program may look the same, recently implemented advancements continue to change the game. According to Interventional ...

Three years after the U.S. FDA approval of Abbott Laboratories’ Amplatzer Amulet, results of its investigational device exemption trial failed to notably differentiate Abbott’s left atrial appendage ...

Abbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) ...

Abbott Park, Illinois Wednesday, November 20, 2024, 13:00 Hrs [IST] ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Next-generation system to be highlighted during a technology innovation session and live case presentation by Professor Jens Erik Nielsen-Kudsk "We are pleased that the CLAAS AcuFORM system is ...

Left atrial appendage closure is an alternative strategy for stroke prophylaxis, Wazni and colleagues noted. "The safety and ...

Left atrial appendage closure is a mechanical alternative to anticoagulation, but data regarding its use after atrial fibrillation ablation are lacking. We conducted an international randomized ...